Table 7. Health worker knowledge of policy for treatment of uncomplicated malaria in the second and third trimesters of pregnancy in Ashanti Region, Ghana (N = 134).

Indicator	N	%	95% CI
Proportion who know that artesunate-amodiaquine (AS–AQ) is the correct drug for malaria treatment in second/third trimesters*	105	78.4	70.7, 84.5
Proportion who know that AS–AQ treatment should be given for 3 days*	120	89.6	81.2, 94.5
Proportion who know AS–AQ should be taken 2 times each day*	125	93.3	85.4, 97.1
Proportion who know that 2 artesunate (AS) tablets should be taken each time	87	64.9	55.3, 73.5
Proportion who know 2 amodiaquine (AQ) tablets should be taken each time	68	50.7	41.4, 60.1
Proportion who know 2AS and 2AQ tablets should be taken each time	66	49.3	39.8, 58.8
Proportion who reported AS–AQ should not be given in the first trimester	99	73.9	64.9, 81.3
Proportion who know the correct drug, dose & duration to treat uncomplicated malaria during second/third trimesters of pregnancy	56	41.8	32.2, 52.0
Proportion who know the correct drug, dose & duration to treat uncomplicated malaria during second/third trimesters of pregnancy, including restrictions on use of AS–AQ during the first trimester.	46	34.3	25.7, 44.1

*Note: the proportion of ANC staff that could report the correct duration of treatment with AS–AQ was higher than those that reported AS–AQ as the first-line drug for treatment of uncomplicated malaria in pregnancy; this is because questions on dose and duration of AS–AQ treatment for a pregnant woman in her second or third trimester were asked to all respondents, irrespective of their answer to the most appropriate drug.